Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A single-cell atlas of normal and KRASG12D-malformed lymphatic vessels
Lorenzo M. Fernandes, Danielle Griswold-Wheeler, Jeffrey D. Tresemer, Angelica Vallejo, Neda Vishlaghi, Benjamin Levi, Abigail Shapiro, Joshua P. Scallan, Michael T. Dellinger
Lorenzo M. Fernandes, Danielle Griswold-Wheeler, Jeffrey D. Tresemer, Angelica Vallejo, Neda Vishlaghi, Benjamin Levi, Abigail Shapiro, Joshua P. Scallan, Michael T. Dellinger
View: Text | PDF
Research Article Angiogenesis Development Vascular biology

A single-cell atlas of normal and KRASG12D-malformed lymphatic vessels

  • Text
  • PDF
Abstract

Somatic activating mutations in KRAS can cause complex lymphatic anomalies (CLAs). However, the specific processes that drive KRAS-mediated CLAs have yet to be fully elucidated. Here, we used single-cell RNA sequencing to construct an atlas of normal and KrasG12D-malformed lymphatic vessels. We identified 6 subtypes of lymphatic endothelial cells (LECs) in the lungs of adult wild-type mice (Ptx3, capillary, collecting, valve, mixed, and proliferating). To determine when the LEC subtypes were specified during development, we integrated our data with data from 4 stages of development. We found that proliferating and Ptx3 LECs were prevalent during early lymphatic development and that collecting and valve LECs emerged later in development. Additionally, we discovered that the proportion of Ptx3 LECs decreased as the lymphatic network matured but remained high in KrasG12D mice. We also observed that the proportion of collecting and valve LECs was lower in KrasG12D mice than in wild-type mice. Last, we found that immature lymphatic vessels in young mice were more sensitive to the pathologic effects of KrasG12D than mature lymphatic vessels in older mice. Together, our results expand the current model for the development of the lymphatic system and suggest that KRAS mutations impair the maturation of lymphatic vessels.

Authors

Lorenzo M. Fernandes, Danielle Griswold-Wheeler, Jeffrey D. Tresemer, Angelica Vallejo, Neda Vishlaghi, Benjamin Levi, Abigail Shapiro, Joshua P. Scallan, Michael T. Dellinger

×

Figure 6

Temporal sensitivity of lymphatic vessels to KrasG12D.

Options: View larger image (or click on image) Download as PowerPoint
Temporal sensitivity of lymphatic vessels to KrasG12D.
(A) Schematics of...
(A) Schematics of the Prox1-CreERT2, R26mT/mG, and KrasLSL-G12D alleles. (B) Schematic showing when mice received tamoxifen (early induction = 50 μg, p.o.; late induction = 2 mg, i.p.). (C) Representative images of ear skin whole mounts stained with an anti-GFP antibody. (D–F) Results for early tamoxifen treatment. (D) Branch points per millimeter vessel for control (2.718 ± 0.07512; n = 6) and KrasG12D (2.086 ± 0.09636; n = 5) mice. (E) Valves per millimeter vessel for control (1.828 ± 0.1274; n = 6) and KrasG12D (0.0760 ± 0.01503; n = 5) mice. (F) Vessel diameters for control (38.12 ± 1.212 μm; n = 6) and KrasG12D (72.89 ± 4.360 μm; n = 5) mice. (G–I) Results for late tamoxifen treatment and early collection. (G) Branch points per millimeter vessel for control (2.122 ± 0.07161; n = 7) and KrasG12D (2.252 ± 0.1862; n = 7) mice. (H) Valves per millimeter vessel for control (2.299 ± 0.1534; n = 7) and KrasG12D (2.133 ± 0.1016 n = 7) mice. (I) Vessel diameters for control (44.25 ± 1.164 μm) and KrasG12D (47.92 ± 0.5579 μm) mice. (J–L) Results for late tamoxifen treatment and late collection. (J) Branch points per millimeter vessel for control (1.947 ± 0.09457; n = 6) and KrasG12D (1.711 ± 0.08402; n = 5) mice. (K) Valves per millimeter vessel for control (1.937 ± 0.1105; n = 6) and KrasG12D (1.948 ± 0.1595; n = 5) mice. (L) Vessel diameters for control (43.26 ± 0.6543 μm; n = 6) and KrasG12D (47.81 ± 1.036 μm; n = 5) mice. Data are presented as mean ± SEM. NS, not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 2-tailed, unpaired Student’s t test (D, E, H, I, J, K, and L) or Mann-Whitney test (F and G). Scale bar: 500 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts